S&P Futures
4,569.75 +6.75 (+0.15%) Dow Futures
35,505.00 +60.00 (+0.17%) Nasdaq Futures
16,067.50 +19.50 (+0.12%) Russell 2000 Futures
1,803.60 +6.60 (+0.37%) Crude Oil
76.43 +0.02 (+0.03%) Gold
2,044.20 +4.20 (+0.21%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 214.42 |
| Open | 214.42 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 213.84 - 214.69 |
| 52 Week Range | 116.08 - 217.51 |
| Volume | |
| Avg. Volume | 1,433,322 |
| Market Cap | 40.404B |
| Beta (5Y Monthly) | 0.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SGEN
Related Research
- Seagen Inc.Analyst Report: Seagen Inc.Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.RatingFair ValueEconomic Moat27 days agoMorningstar
- Business Wire
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
BOTHELL, Wash., November 03, 2023--Seagen Inc. (NASDAQ: SGEN) today announced the first presentation of data evaluating ADCETRIS® (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and shared preclinical data for an investigational CD30-directed antibody-drug conjugate (ADC) that uses a novel tripeptide linker. The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place
- Business Wire
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
BOTHELL, Wash., November 02, 2023--Seagen Inc. (NASDAQ: SGEN) today announced that 12- and 24-month progression free survival data will be presented for an ADCETRIS® (brentuximab vedotin) and immunotherapy combination in early and advanced stage classical Hodgkin lymphoma (cHL), respectively. The data will be featured in two oral presentations at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 9-12, 2023 in San Diego. The ongoing Phase 2 clinical
- Business Wire
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
BOTHELL, Wash., November 01, 2023--Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023.
